Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Preferred Stock Liabilities (2017 - 2021)

Cogent Biosciences' Preferred Stock Liabilities history spans 4 years, with the latest figure at $85.4 million for Q3 2021.

  • Quarterly Preferred Stock Liabilities fell 38.22% to $85.4 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $85.4 million through Sep 2021, down 38.22% year-over-year, with the annual reading at $110.9 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities came in at $85.4 million for Q3 2021, roughly flat from $85.4 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $138.2 million in Q3 2020 to a low of $77.2 million in Q4 2017.
  • The 4-year median for Preferred Stock Liabilities is $85.4 million (2021), against an average of $95.6 million.
  • The largest YoY upside for Preferred Stock Liabilities was 38.22% in 2021 against a maximum downside of 38.22% in 2021.
  • Cogent Biosciences' Preferred Stock Liabilities stood at $77.2 million in 2017, then rose by 0.02% to $77.2 million in 2018, then surged by 43.69% to $110.9 million in 2020, then fell by 22.98% to $85.4 million in 2021.
  • Per Business Quant, the three most recent readings for COGT's Preferred Stock Liabilities are $85.4 million (Q3 2021), $85.4 million (Q2 2021), and $94.7 million (Q1 2021).